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Purpose of the study
To know the main epidemiological, virological and therapeutic characteristics of HCV infection and the degree of hepatic fibrosis
in a cohort of HIV-HCV co-infected patients in a health area of southeastern of Spain.
Methods
Prospective cohort of co-infected HIV-HCV patients followed in the University Hospital of Saint Lucia (Spain), which describes the
main epidemiological characteristics, degree of liver fibrosis assessed by transient elastography and the level of response to
treatment for HCV during the period November 30, 2011February 28, 2012.
Summary of results
The cohort included 109 patients, of whom 27 were females (25%) and 82 males (75%), with a mean age of 45.8 (SD: 6.2) years
and a mean time of infection of 18.8 (SD: 5.7) years.The main route of transmission was in this order: IDUs in 90 patients (83%),
13 (12%) by heterosexual intercourse and 3 (2.8%) in MSM.There were no statistically significant differences between the years
of evolution of HCV based on the route of transmission (p0.36). In the genotypic analysis, 55 patients were genotype
1a (51%), 13 genotype 1b (13%), 19 genotype 3 (17%) and 9 genotype 4 (8.3%). The median HCV viral load was 868,000 IU/ml
(6.15 log10). In this cohort 31 patients (28%) received antiviral therapy for HCV: 2 (1.8%) Interferon (INF) non-pegylated, 3 (2.8%)
INF non-pegylated with Ribavirin (RBV) and 25 (23%) INF pegylated with RBV. In 6 cases (19%) were achieved sustained viral
response (SVR). In the 25 cases without SVR (81%), 9 (36%) were partial responders, 7 (28%) null responders, 6 (24%) relapsers
and 3 (12%) discontinued treatment due to problems of tolerability. In 108 patients were determined the degree of liver fibrosis
by transient elastography: 48 patients (44%) had significant fibrosis (F3F4;9.5 kpascal) and 30 (28%) liver cirrhosis (F4;14.5
kpascal). In patients with F4, 5 (17%) had values between 14.520 kpascal, 14 (47%) values between 2140 kpascal and
11 (37%) values over 40 kpascal.
Conclusions
In our cohort, the gender predominant was male and the abuse of intravenous drugs was the main cause of HCV transmission.
Most patients had genotype 1a, high viral load (800,000 UI/mL) and a poor rate of SVR (19.3%), predominating the partial
response rate among non-responders. A high proportion of patients (28%) had liver cirrhosis (F4), of which, a significant
proportion of subjects (37%) were at high risk of hepatic decompensation (40 kpascal).
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